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Abstract: Background: Statins (3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors) exert favorable effects on lipopro-
tein metabolism, but appeared to possess anti-inflammatory properties among others, as suggested by their ability to in-
hibit collagen-induced arthritis in mice. Their activity in fibroblast-like synovial cells (FLS) has not yet been studied. 
Objectives: To evaluate the effect of varying doses of simvastatin on apoptosis of FLS. 
Methods: Synovial tissue, obtained during total knee replacement due to osteoarthritis, was cut into small pieces and cul-
tured in Petri dishes with test materials, as previously described. FLS were incubated for 48 hours with 1 μmol/ml, 5 
μmol/ml, 15 μmol/ml and 50 μmol/ml of simvastatin. Following incubation, apoptosis was analyzed by two-dimensional 
flow cytometry (FACS) using annexin V/PI staining according to the manufacturer’s instructions. 
Results: Different concentrations of simvastatin induced apoptosis of FLS. The level proportion of apoptotic cells of rest-
ing or activated with lipopolysaccharide (LPS; 3 μg/ml) FLS, not treated with simvastatin, was 21%. At 48 hours, the rate 
of apoptosis of activated fibroblasts, incubated with 1 μmol/ml, 5 μmol/ml, 15 and 50 μmol/ml was 22%, 32%, 48% and 
41% respectively. Synovial cell viability evaluated by tetrazolium salt XXT was unaffected by the simvastatin concentra-
tion used. 
Conclusion: Varying concentrations of simvastatin induce apoptosis of activated fibroblast-like synoviocytes, suggesting 
another possible mechanism of anti-inflammatory effects of statins in inflammatory conditions. 
Keywords: Apoptosis, inflammation, simvastatin, fibroblast-like synoviocytes. 
INTRODUCTION 
  Statins are potent inhibitors of 3-hydroxy-3methylglut-
aryl coenzyme A (HMG-CoA) reductase, the rate-limiting 
enzyme of the cholesterol synthetic pathway, and they are 
widely used to treat hyperlipidemia. The beneficial effects of 
statins have been attributed primarily to their ability to in-
hibit cholesterol synthesis. They block the conversion of 
HMG-CoA to mevalonate at the start of the cholesterol bio-
synthetic pathway with a subsequent increase in LDL-
receptor expression on the hepatocyte, resulting in a further 
reduction of plasma LDL-cholesterol level [1]. 
  Although statins are considered to be the most effective 
drugs for treating hypercholesterolemia [2], the reduction in 
cardiovascular events observed in patients treated with stat-
ins is not fully explained by the reduction in LDL-
cholesterol: this has been in part attributed to the ability of 
statins to modulate several mechanisms involved in the in-
flammatory process [3]. Better survival of heart transplant 
patients treated with statins has been attributed to their im-
munomodulatory effects [4] and reports of improvement of 
Rheumatoid Arthritis (RA) patients [5] lend support to the 
clinical anti-inflammatory role of statins. 
  Inflammatory processes are involved in atherosclerosis 
[3, 6]. A number of studies suggest that in addition to their  
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lipid-lowering activity, statins may influence atherosclerosis 
and cardiovascular diseases through the down regulation of 
the inflammatory response [7]. Statins has been shown to 
reduce plasma levels of TNF-alpha, sP selectin and IL-6 in 
long term survivors of heart transplantation and in patients 
with cholesterolemia, without known cardiovascular disease 
[8, 9]. 
 Some  in vitro experiments and studies in animal models 
have also found that these agents may down regulate in-
flammatory responses such as the production of pro-
inflammatory cytokines, chemokines and adhesion mole-
cules; these agents may also reduce the expression of induc-
ible major histocompatibility complex (MHC) class II mole-
cules by antigen presenting cells [10]. 
  Rheumatoid arthritis (RA) is a chronic inflammatory 
joint disease characterized by synovial proliferation and ab-
normal immune responses, eventually causing erosion of the 
affected joint. Marked infiltration of lymphocytes, macro-
phages, and plasma cells is observed in the synovial tissue of 
RA [11]. Apoptosis of macrophages and fibroblast-like 
synoviocytes has been observed in rheumatoid synovium 
[12, 13]. It has been suggested that reduced apoptosis con-
tributes to the synovial inflammatory process [12]. In vitro 
statins were shown to exert a cytotoxic effect on human T, B 
and myeloma cells by promoting their apoptosis [14] and 
also modifying apoptosis of smooth muscle and endothelial 
cells leading to altered vascular function and neovascularisa-
tion [15]. 36    The Open Rheumatology Journal, 2009, Volume 3  Litinsky et al. 
  We studied the effects of different doses of simvastatin 
on apoptosis of fibroblast–like synoviocytes (FLS). 
MATERIALS AND METHODS 
Specimen Selection and Culture Conditions 
  Synovial tissue was obtained during surgery from 3 pa-
tients undergoing total knee replacement because of os-
teoarthritis (OA). Synovial cells derived from small pieces (~ 
2mm diameter) of human synovial tissue was first grown in 
T 15 culture flasks, by methods described by Castor et al. 
[16]. Then the cells identified as fibroblasts by the method of 
Castor [17] originating from the tissue samples were inocu-
lated in T-15 culture flasks and incubated at 37ºC. Cell were 
grown as monolayers in 6 or 7 day growth (between on 
trypsinization and another), then trypsinized and replated 
until there were enough cells for an experiment to be per-
formed [17]. the culture medium consisted of RPMI 1640 
supplemented by L-glutamine (2 mM) (Sigma, Israel), peni-
cillin (100 U/ml), and streptomycin sulphate (100 U/ml) and 
10% fetal calf serum (FCS, Bet-Haemek, Israel). Experi-
ments were performed in 96 well plates containing 15-
2010
5 cells/well in a serum free medium for 48 hours at 
37
0C (in 5% CO2). 
  The LPS and simvastatin treatments were carried out 
with isolated cells in tissue culture cells and were incubated 
for 48 hours, using different concentrations of simvastatin: 1, 
5, 15 and 50 μmol/ml. Stimulation of the cell culture (FLS) 
with lipopolysaccharide (LPS) was performed as previously 
described [18]. After collection of the cells, the incubation 
period of the cells with simvastatin lasted 48 hours. 
  The clinical research was conducted in accordance with 
guidelines for human experimentation specified by the Tel 
Aviv Sourasky Medical Center. The study was approved by 
the Ethics Committee of the Medical Center. 
Apoptosis Assay 
  After 48 hours incubation in varying concentrations of 
simvastatin, fibroblast-like synovial cells were detached and 
placed in a serum free medium for 48 hours. Apoptosis was 
analyzed by two-dimensional flow cytometry, using annexin 
V and propidium iodide according to the manufacturer’s 
instructions (Biotest). Flow cytometry was then performed 
using a Becton Dickinson FACSort flow cytometer (Becton 
Dickinson, San Jose, CA, USA). Events accumulating at the 
top and bottom right-hand quadrates simulated apoptotic 
cells. 
Cell Viability and Toxicity Determination 
  Cell viability in the presence of statins was determined in 
human synovial cultures by tetrazolium salt XTT assay at the 
end of the experiment. 
  XTT is a tetrazolium derivative that measures cell viabil-
ity based on the activity of mitochondria enzymes in live 
cells that reduce XTT and are inactivated shortly after cell 
death. XTT is readily reduced to a highly water-soluble or-
ange colored. The amount of water-soluble product gener-
ated from XTT is proportional to the number of living cells 
in the sample and can be quantified by measuring absor-
bance at wavelength of 475 nm. 
 
Statistical Analysis 
  Statistical analysis was evaluated by analysis of variance 
and by Student's t test. P values of less than 0.05 were con-
sidered statistically significant. Individual experiments were 
performed in triplicates. Results represent the findings from 
several separate experiments. 
RESULTS 
Apoptosis 
  Simvastatin induced apoptosis of human fibroblasts in a 
dose dependent manner. The proportion of apoptotic cells of 
resting or activated human fibroblasts lipopolysaccharide 
(LPS; 3μg/ml) not treated with simvastatin was 21% (Fig. 1). 
At 48 hours, the proportion of apoptosis of fibroblasts acti-
vated by LPS and incubated with 1, 5, 15 and 50 μmol/ml 
was 22%, 32%, 48% and 41% respectively (Fig. 2). 
Cell Viability 
  Synovial cell viability evaluated by tetrazolium salt XTT 
was unaffected by the simvastatin concentration used in 
these experiments [19]. 
DISCUSSION 
  In this study, we have shown that simvastatin in doses 
within the therapeutic range causes a dose dependent induc-
tion of apoptosis of fibroblast-like synoviocytes activated 
with LPS. Despite the apoptotic effect of simvastatin, cell 
viability was not affected, suggesting that the level of apop-
tosis was limited. Our results are consistent with the data 
reported by Yokota et al. who have shown that high concen-
trations of simvastatin induce apoptosis of fibroblast-like-
cells [20]. 
  Inflammation of synovial tissue in rheumatoid arthritis is 
a complex sequence of events involving different cell lines 
and many soluble factors such as cytokines and chemokines. 
  A possible way to reduce the inflammatory burden may 
include an induction of apoptosis of cells involved in the 
inflammatory process. Several drugs, such as COX-2 inhibi-
tors [21], methotrexate and corticosteroids [22] promote 
apoptosis of T cells. It has been recently shown that anti-
tumor necrosis factor therapy with both etanercept and in-
fliximab significantly increases apoptosis in the synovial 
monocyte/macrophage population [23]. 
  Lovastatine and cerivastatin exert a cytostatic effect on 
mesothelioma [24], glioma [25], neoplastic thyroid [26], 
acute myeloid leukemia [27], multiple myeloma cells [28] 
and lung fibroblast [29] by directly promoting apoptosis. In 
myeloma cells, the apoptotic pathway engaged by statins is 
mediated by mitochondria activation, rather than by the 
“death receptors”, and both caspases 3 and 9 appear to be 
directly involved and activated within the intrinsic pathway 
of apoptosis [30]. Statins also enhance the rate of apoptosis 
in neointimal smooth muscle cells [31]. Recently Nagashima 
et al. have shown that fluvastatin but not pravastatin, in-
duced apoptosis in RA synoviocytes in a dose and time de-
pendent manner [32]. Consistent with this report our study 
has demonstrated that simvastatin may also induce apoptosis 
of synovial cells. 
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  Recent publications have identified a therapeutic use of 
statins in the treatment of various models of autoimmunity 
[33, 34]. Leung et al. have shown that simvastatin markedly 
inhibited not only developing but also clinically evident col-
lagen-induced arthritis [34]. Ex-vivo analysis demonstrated a 
significant suppression of collagen-specific Th1 humoral and  
 
cellular immune responses and reduction in anti-CD3/anti-
CD28 proliferation and INF- release from mononuclear 
cells derived from peripheral blood and synovial fluid caused 
by simvastatin [34]. Proinflammatory cytokine production in 
vitro by T cell contact-activated macrophages was also sup-
pressed by simvastatin. Likewise, there are several   
 
 
Fig. (1). The level of apoptosis of human fibroblasts, resting or activated with LPS in the absence of simvastatin. The level of apoptosis is 
among 19% to 21%. 
The level of apoptosis of resting or activated with lipopolysaccaride (LPS; 3μg/ml) human fibroblasts in the medium of synovial culture tis-
sue not treated with simvastatin. Apoptosis was analyzed by two-dimensional flow cytometry using annexin V and propidium iodide accord-
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indications suggesting a beneficial effect of statins on multi-
ple sclerosis [34] and, in particular, in the mouse model of 
multiple sclerosis-termed experimental autoimmune en-
cephalomyelitis [33]. Youssef et al. have shown that oral 
statin treatment prevents chronic and relapsing paralysis and 
suppresses clinical and histological EAE. Statin treatment 
reduced CNS infiltration of TH1 lymphocytes and MHC 
class II expression, inhibited the activity of CD 40, CD80 
and CD86 co stimulatory molecules, largely inhibited the 
secretion of inflammatory cytokines such as TNF, INF and 
even induced the production of anti inflammatory cytokines 
[33]. 
(Fig. 2). Contd….. 
 
Fig. (2). The levels of apoptosis of human fibroblasts activated by LPS, treated with different doses of simvastatin. A dose dependent apop-
tosis of FLS can be observed: the level of apoptosis under 1 mcmol/ml is similar to untreated cells while 15 mcrmo/ml of simvastatin induce 
apoptosis of more than 48 %.  
Dose-dependent effects of simvastatin on the levels of apoptosis of human fibroblasts-like synoviocytes in the medium of synovial culture 
activated by LPS (3μg/ml). The proportion of apoptosis of activated human fibroblasts-like synoviocytes was measured after 48 hours incu-
bation with different doses of simvastatin: (A) Simvastatin 1 μmol/ml; (B) Simvastatin 5 μmol/ml; (C) Simvastatin 15 μmol/ml; (D) Simvas-
tatin 50 μmol/ml. 40    The Open Rheumatology Journal, 2009, Volume 3  Litinsky et al. 
  In conclusion, our results demonstrate that simvastatin 
stimulates apoptosis of human synovial cells in vitro. We are 
aware of the limitations of this study which assessed apopto-
sis by Annexin PI staining without confirming the results 
using other methods. Further research is warranted to estab-
lish the in vivo relevance of these findings. Recently, in-
creased cardiovascular morbidity and mortality have been 
observed in several inflammatory rheumatic diseases, includ-
ing rheumatoid arthritis (RA) [35], encouraging aggressive 
treatment of the inflammatory process, as well as vigorous 
neutralization of traditional risk factors of atherosclerosis 
such as hypercholesterolemia. Our study further supports the 
use of statins in this subset of patients, suggesting an addi-
tional anti immunomodulatory effect. 
REFERENCES 
[1]  Aguilar-Salinas SA, Barrett H, Schonfeld G. Metabolic modes of 
action of statins in the hyperlipoproteinemias. Atherosclerosis 
1998; 141: 203-7. 
[2]  Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute 
coronary events with lovastatin in men and women with average 
cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 
279: 1615-22. 
[3]  Case CC, Ballantyne CM. Statins and inflammatory markers. Curr 
Atheroscler Rep 2002; 4: 42-7. 
[4]  Bilchick KC, Henrikson CA, Skojec D, Kasper EK, Blumenthal 
RS. Treatment of hyperlipidemia in cardiac transplant recipients. 
Am Heart J 2004; 148: 200-10. 
[5]  McCarey DW, McInnes IB, Madhok R, et al. Trial of atorvastatin 
in rheumatoid arthritis (TARA): double-blind, randomized placebo-
controlled trial. Lancet 2004; 363: 2015-21. 
[6]  Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-
Reactive protein for the targeting of statin therapy in the primary 
prevention of acute coronary events. N Engl J Med 2001; 344: 
1959-65. 
[7]  Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive 
protein with cervastatin among 785 patients with primary hyper-
cholesterolemia. Circulation 2001; 103: 1191-3. 
[8]  Torborn H, Andreassen AK, Ueland T, et al. Effect of pravastatin 
on plasma markers of inflammation and peripheral endothelial 
function in male heart transplant recipients. Am J Cardio 2001; 87: 
815-18. 
[9]  Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflamma-
tory cytokine production by pravastatin. Lancet 1999; 353: 983-84. 
[10]  Jury EC, Ehrenstein MR. Statins: immunomodulators for autoim-
mune rheumatic disease? Lupus 2005; 14: 192-6. 
[11]  Gay S, Gay RE, Koopman WJ. Molecular and cellular mechanisms 
of joint destruction in rheumatoid arthritis: two cellular mecha-
nisms explain joint destruction. Ann Rheum Dis 1993; 52: S39-
S47. 
[12]  Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis 
synovium. J Clin Invest 1995; 96: 1631-38. 
[13]  Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Im-
munol Today 1995; 16: 39-43. 
[14]  Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate 
the mitochondrial pathway of apoptosis in human lymphoblasts and 
myeloma cells. Carcinogenesis 2005; 26(5): 883-91. 
[15]  Muck AO, Seeger H, Wallwiener D. Class-specific pro-apoptotic 
effect of statins on human vascular endothelial cell. Z Kardiol 
2004; 93: 398-402. 
[16]  Castor CW, Bignell MC, Hossler PA, Roberts D. Connective tissue 
activation. XXI. Regulation of glycisaminoglycan metabolism by 
lymphocytes (CTAP-1) and platelet (CTAP-III) growth factors. In 
Vitro Cell Dev Biol 1981; 17: 777-85. 
[17]  Castor CW, Prince RK, Dorstewitz EL. Characteristics of human 
fibroblasts cultivated in vitro from different anatomical sites. Lab 
Invest 1962; 11: 703-13. 
[18]  Yaron I, Shirazi E, Yudovich R, Caspi D, Levartovsky D, Yaron 
M. Fluoxetine and amitriptilline inhibit nitric oxide, prostaglandin 
E2 and hyaluronic acid production in human synovial cells and 
synovial tissue cultures. Arthritis Rheum 1999; 42: 2561-8. 
[19]  Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. An im-
proved colorimetric assay for cell proliferation and viability using 
the tetrazolium salt XTT. J Immunol Methods 1991; 142; 257-65. 
[20]  Yokota K, Miyoshi F, Miyzaki T, et al. High concentration simvas-
tatin induces apoptosis in fibroblast-like synoviocytes from patients 
with rheumatoid arthritis. J Rheumatol 2008; 35: 193-200. 
[21]  Yim HW, Jong HS, Choi HH, et al. Cyclooxygenase-2 inhibits 
novel ginseng metabolite - mediated apoptosis. Cancer Res 2005; 
65: 1952-60. 
[22]  Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Gawronska-
Szklarz B. The effect of methotrexate and glucocorticosteroids on 
apoptosis of phythemaglutinin-stimulated mononuclear cells from 
peripheral blood. Fundam Clin Pharmacol 2005; 19: 81-5. 
[23]  Catrina AI, Trollmo C, af Klint E, et al. Evidence that anti-tumor 
necrosis factor therapy with both etanercept and infliximab induces 
apoptosis in macrophages, but not lymphocytes, in rheumatoid ar-
thritis joints: extended report. Arthritis Rheum 2005; 52: 61-72. 
[24]  Rubins JB, Greatens T, Kratzke RA, Tan AT, Polunovsky VA, 
Bitterman P. Lovastatin induces apoptosis in malignant mesothe-
lioma cells. Am J Respir Crit Care Med 1998; 157: 1616-22. 
[25]  Jones KD, Couldwell WT, Hinton DR, et al. Lovastatin induces 
growth inhibition and apoptosis in human malignant glioma cells. 
Biochem. Biophys Res Commun 1994; 205: 1681-7. 
[26]  Vitale M, Di Matola T, Rossi G, Laezza C, Fenzi G, Bifulco M. 
Prenytransferase inhibitors induce apoptosis in proliferating thyroid 
cells through a p53-independent, CrmA-sensitive, and caspase-3 
like protease dependent mechanism. Endocrinology 1999; 140: 
698-704. 
[27]  Wong WWL, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn 
LZ. Cerivastatin triggers tumor-specific apoptosis with higher effi-
cacy than lovastatin. Clin Cancer Res 2001; 7: 2067-75. 
[28]  Van de Donk NWCJ, Kamphuis MM, Lokhorst HM, Bloem AC. 
The cholesterol lowering drug lovastatin induces cell death in mye-
loma plasma cells. Leukemia 2002; 16: 1362-71. 
[29]  Tan A, Levrey H, Dahm C, Polunovsky VA, Rubins J, Bitterman 
PB. Lovastatin induces fibroblast apoptosis in vitro and in vivo. 
Apossible therapy for fibroproliferative disorders. Am J Respir Crit 
Care Med 1999; 159: 220-27. 
[30]  Cafforio P, Dammacco F, Gernome A, Silvestris F. Statins activate 
the mitochondrial pathway of apoptosis in human lymphoblasts and 
myeloma cells. Carcinogenesis 2005; 26: 883-91. 
[31]  Erl W, Hristov M, Neureuter M, Yan ZQ, Hansson GK, Weber PC. 
HMG-CoA reductase inhibitors induce apoptosis in neointima-
derived vascular smooth muscle cells. Atherosclerosis 2003; 
169(2): 251-8. 
[32]  Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S. Apop-
tosis of rheumatoid synovial cells by statins through the blocking of 
protein geranylgeranylation. Arthritis Rheum 2006; 54: 579-86. 
[33]  Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase 
inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis 
in central nervous system autoimmune disease. Nature 2002; 420: 
78-84. 
[34]  Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role 
for simvastatin in inflammatory arthritis. J Immunol 2003; 170(3): 
1524-30. 
[35]  Del Rinco´n I, Williams K, Stern MP, Freeman GL, Escalante A. 
High incidence of cardiovascular events in a rheumatoid arthritis 
cohort not explained by traditional cardiac risk factors. Arthritis 
Rheum 2001; 44: 2737-45. 
 
 
Received: February 16, 2009  Revised: February 26, 2009  Accepted: March 24, 2009 
 
© Litinsky et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 